Skip to main content

Table 5 Univariate analysis of potential prognostic factors

From: Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma

W

OS

PFS

DMFS

 

HR (95%CI)

P

HR (95%CI)

P

HR (95%CI)

P

Gender

0.74 (0.369–1.485)

0.397

0.849 (0.465–1.550)

0.595

1.70 (0.511–5.659)

0.387

Age (years)

1.713 (0.958–3.065)

0.07

1.441 (0.861–2.411)

0.164

0.641 (0.203–2.022)

0.448

Recurrent time

1.048 (0.588–1.867)

0.874

0.99 (0.586–1.671)

0.969

0.815 (0.258–2.570)

0.727

Recurrent T classification

3.716 (1.332–10.370)

0.012

2.005 (0.949–4.236)

0.068

1.531 (0.332–7.063)

0.595

Lymph node recurrence

0.727 (0.390–1.354)

0.315

0.699 (0.402–1.217)

0.206

1.378 (0.437–4.343)

0.585

EBV DNA prior to RT

1.061 (0.589–1.911)

0.843

1.199 (0.716–2.006)

0.491

1.245 (0.393–3.945)

0.709

EBV DNA following RT

1.563 (0.796–3.069)

0.195

1.664 (0.919–3.013)

0.092

3.294 (1.016–10.680)

0.047

Tumor response

1.791 (1.002–3.201)

0.049

1.455 (0.867–2.443)

0.155

0.681 (0.214–2.166)

0.515

Treatment modalities

1.103 (0.625–1.946)

0.736

0.908 (0.543–1.519)

0.713

0.871 (0.276–2.745)

0.813

GTV-T volume (cm3)

2.844 (1.539–5.257)

0.001

2.085 (1.224–3.553)

0.007

2.425 (0.714–8.230)

0.155

HB baseline

0.56 (0.313–1.001)

0.05

0.609 (0.361–1.027)

0.063

0.702 (0.209–2.352)

0.566

  1. HR hazard ratio; CI confidence interval; OS overall survival; PFS, progression-free survival; DMFS, distant metastasis-free survival; EBV, Epstein-Barr virus; HB, hemoglobin. A Cox proportional hazards model was used to perform univariable analyses. All variables were transformed into categorical variables. HRs were calculated for gender (male vs. female); age (years) (< 50 vs. ≥50); recurrent time (< 36 months vs. ≥36 months); recurrent T classification (rT1–2 vs. rT3–4); lymph node recurrence (no vs. yes); EBV DNA prior to RT (negative vs. positive); EBV DNA following RT (negative vs. positive); tumor response (CR + PR vs. SD + PD); treatment modalities (chemotherapy vs. N); GTV-T volume (cm3) (< 30 vs. ≥30); and HB baseline (g/L) (< 135 g/L vs. ≥135 g/L).HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; DMFS, distant metastasis-free survival; EBV, Epstein-Barr virus; HB, hemoglobin. A Cox proportional hazards model was used to perform univariable analyses. All variables were transformed into categorical variables. HRs were calculated for gender (male vs. female); age (years) (< 50 vs. ≥50); recurrent time (< 36 months vs. ≥36 months); recurrent T classification (rT1–2 vs. rT3–4); lymph node recurrence (no vs. yes); EBV DNA prior to RT (negative vs. positive); EBV DNA following RT (negative vs. positive); tumor response (CR + PR vs. SD + PD); treatment modalities (chemotherapy vs. N); GTV-T volume (cm3) (< 30 vs. ≥30); and HB baseline (g/L) (< 135 g/L vs. ≥135 g/L)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us